Review

goat anti mouse vegf polyclonal ab (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems goat anti mouse vegf polyclonal ab
Goat Anti Mouse Vegf Polyclonal Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti mouse vegf polyclonal ab/product/R&D Systems
Average 94 stars, based on 15 article reviews

goat anti mouse vegf polyclonal ab - by Bioz Stars, 2026-06

94/100 stars

Images

Image Search Results

FIGURE 2. Angiogenesis induced by macrophages is IL-1 dependent. Supernatants of macrophages, were prepared as described in Fig. 1, were added to Matrigel as such or after incubation with Abs against IL-1, IL-1, or TNF- and then injected into WT mice. Supernatants were also injected into IL-1R KO mice. A, Mean MVD (SEM, n 5) in Matrigel plugs. B, Mean MVD (SEM, n 5) in Matrigel plugs containing LPS-activated macrophage supernatants derived from IL-1-deﬁcient mice. C, Mean VEGF levels (SEM, n 4) in Matrigel plug extracts as measured by ELISA. D, Mean IL-1 levels (SEM, n 4) in Matrigel plug extracts as measured by ELISA. E, Aorta rings from WT mice were incubated with LPS-activated macrophage supernatants or with recombinant VEGF, and subsequently, sprouting was observed. Photographs (40) were taken 5 days later, and the ﬁgure represents one of ﬁve experiments.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis.

doi: 10.4049/jimmunol.0901511

Figure Lengend Snippet: FIGURE 2. Angiogenesis induced by macrophages is IL-1 dependent. Supernatants of macrophages, were prepared as described in Fig. 1, were added to Matrigel as such or after incubation with Abs against IL-1, IL-1, or TNF- and then injected into WT mice. Supernatants were also injected into IL-1R KO mice. A, Mean MVD (SEM, n 5) in Matrigel plugs. B, Mean MVD (SEM, n 5) in Matrigel plugs containing LPS-activated macrophage supernatants derived from IL-1-deﬁcient mice. C, Mean VEGF levels (SEM, n 4) in Matrigel plug extracts as measured by ELISA. D, Mean IL-1 levels (SEM, n 4) in Matrigel plug extracts as measured by ELISA. E, Aorta rings from WT mice were incubated with LPS-activated macrophage supernatants or with recombinant VEGF, and subsequently, sprouting was observed. Photographs (40) were taken 5 days later, and the ﬁgure represents one of ﬁve experiments.

Article Snippet: Anti-CXCR4 (247506), anti-VEGFR1 (FAB4711A), and polyclonal goat anti-mouse VEGF Abs were purchased from R&D Systems.

Techniques: Incubation, Injection, Derivative Assay, Enzyme-linked Immunosorbent Assay, Recombinant

FIGURE 4. Endothelial lineage cells secrete VEGF in Matrigel plugs, whereas myeloid cells produce IL-1. Inﬁltrating cells were recovered from day 8 Matrigel plugs containing LPS-stimulated macrophage supernatants. Total cells represent supernatants derived from all the inﬁltrating cells recovered from day 8 Matrigel plugs. Anti-CD11b (CD11b) represents supernatants from recovered cells depleted of CD11b-positive cells. Anti-VEGFR2 (VEGFR2) represents supernatants from cells lacking VEGFR2. Cell separation by negative selection on magnetic beads was described in Materials and Methods. A, Levels of IL-1, IL-1, and VEGF (SEM, n 3) secreted by cells recovered from Matrigel plugs and further incubated for 24 h in culture. B, Aorta rings from WT mice were incubated with supernatants of cells recovered from Matrigel plugs (see A), and sprouting of EC from the aorta rings was tested on day 4 (n 3) (40). C, FACS analysis of VEGF and IL-1-producing cells recovered from Matrigel plugs on day 8. D, Mean VEGF levels (SEM, n 3) in day 8 Matrigel plugs extracts obtained from BM chimeric mice.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis.

doi: 10.4049/jimmunol.0901511

Figure Lengend Snippet: FIGURE 4. Endothelial lineage cells secrete VEGF in Matrigel plugs, whereas myeloid cells produce IL-1. Inﬁltrating cells were recovered from day 8 Matrigel plugs containing LPS-stimulated macrophage supernatants. Total cells represent supernatants derived from all the inﬁltrating cells recovered from day 8 Matrigel plugs. Anti-CD11b (CD11b) represents supernatants from recovered cells depleted of CD11b-positive cells. Anti-VEGFR2 (VEGFR2) represents supernatants from cells lacking VEGFR2. Cell separation by negative selection on magnetic beads was described in Materials and Methods. A, Levels of IL-1, IL-1, and VEGF (SEM, n 3) secreted by cells recovered from Matrigel plugs and further incubated for 24 h in culture. B, Aorta rings from WT mice were incubated with supernatants of cells recovered from Matrigel plugs (see A), and sprouting of EC from the aorta rings was tested on day 4 (n 3) (40). C, FACS analysis of VEGF and IL-1-producing cells recovered from Matrigel plugs on day 8. D, Mean VEGF levels (SEM, n 3) in day 8 Matrigel plugs extracts obtained from BM chimeric mice.

Article Snippet: Anti-CXCR4 (247506), anti-VEGFR1 (FAB4711A), and polyclonal goat anti-mouse VEGF Abs were purchased from R&D Systems.

Techniques: Derivative Assay, Selection, Magnetic Beads, Incubation

FIGURE 1. VEGF-RI and -RII RT-PCR. To detect the two VEGF-Rs on synovial cells, VEGF-RI and VEGF-RII mRNAs were ampliﬁed by RT-PCR as described in Materials and Methods. Transcripts of the ex- pected sizes were detected: 482 bp (VEGF-RI) and 448 bp (VEGF-RII). Lane a, The presence of VEGF-RI mRNA in synovial cells from arthritic joints; lane b, positive controls for VEGF-RI from mouse lungs; lane c, size ladder; lane d, positive controls for VEGF-RII from mouse lungs; lane e, the presence of VEGF-RII mRNA in synovial cells from arthritic joints.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

doi: 10.4049/jimmunol.171.9.4853

Figure Lengend Snippet: FIGURE 1. VEGF-RI and -RII RT-PCR. To detect the two VEGF-Rs on synovial cells, VEGF-RI and VEGF-RII mRNAs were ampliﬁed by RT-PCR as described in Materials and Methods. Transcripts of the ex- pected sizes were detected: 482 bp (VEGF-RI) and 448 bp (VEGF-RII). Lane a, The presence of VEGF-RI mRNA in synovial cells from arthritic joints; lane b, positive controls for VEGF-RI from mouse lungs; lane c, size ladder; lane d, positive controls for VEGF-RII from mouse lungs; lane e, the presence of VEGF-RII mRNA in synovial cells from arthritic joints.

Article Snippet: Anti-mouse VEGF and VEGF-R Abs The neutralizing polyclonal goat anti-mouse-VEGF Ab was obtained from R&D Systems Europe (Abingdon, U.K.).

Techniques: Reverse Transcription Polymerase Chain Reaction

FIGURE 3. Equal amounts of cultured synovial cell protein extract (20 g) from arthritic and normal mice and mouse lungs (positive control) were dissolved in Laemmli buffer and then submitted to SDS-PAGE in 10% acrylamide gels. After transfer onto nitrocellulose membranes, the membranes were probed with the primary Ab (anti-VEGF-RI and anti- VEGF-RII) and revealed with a peroxidase-labeled secondary Ab. Bands of the expected sizes (151 and 150 kDa) were observed in the arthritic mice and in the positive control. Bands were scanned with an HP scan jet 5500, and the ratio between bands from arthritic mice and the positive control was calculated. The results are representative of three experiments.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

doi: 10.4049/jimmunol.171.9.4853

Figure Lengend Snippet: FIGURE 3. Equal amounts of cultured synovial cell protein extract (20 g) from arthritic and normal mice and mouse lungs (positive control) were dissolved in Laemmli buffer and then submitted to SDS-PAGE in 10% acrylamide gels. After transfer onto nitrocellulose membranes, the membranes were probed with the primary Ab (anti-VEGF-RI and anti- VEGF-RII) and revealed with a peroxidase-labeled secondary Ab. Bands of the expected sizes (151 and 150 kDa) were observed in the arthritic mice and in the positive control. Bands were scanned with an HP scan jet 5500, and the ratio between bands from arthritic mice and the positive control was calculated. The results are representative of three experiments.

Article Snippet: Anti-mouse VEGF and VEGF-R Abs The neutralizing polyclonal goat anti-mouse-VEGF Ab was obtained from R&D Systems Europe (Abingdon, U.K.).

Techniques: Cell Culture, Positive Control, SDS Page, Labeling

FIGURE 5. Effect of anti-mouse VEGF Ab treatment on the clinical course of arthritis in K/BxN transgenic mice. The incidence and severity of arthritis were assessed daily in anti-mouse-VEGF-treated (; n 9) and isotype-treated (; n 11) mice. Arthritis was quantiﬁed by measuring the thickness of each paw with an electronic caliper square. The sum of the measures of the four paws (in millimeters) was used as the AI. Results are expressed as the mean SD. , p 0.05.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

doi: 10.4049/jimmunol.171.9.4853

Figure Lengend Snippet: FIGURE 5. Effect of anti-mouse VEGF Ab treatment on the clinical course of arthritis in K/BxN transgenic mice. The incidence and severity of arthritis were assessed daily in anti-mouse-VEGF-treated (; n 9) and isotype-treated (; n 11) mice. Arthritis was quantiﬁed by measuring the thickness of each paw with an electronic caliper square. The sum of the measures of the four paws (in millimeters) was used as the AI. Results are expressed as the mean SD. , p 0.05.

Article Snippet: Anti-mouse VEGF and VEGF-R Abs The neutralizing polyclonal goat anti-mouse-VEGF Ab was obtained from R&D Systems Europe (Abingdon, U.K.).

Techniques: Transgenic Assay

FIGURE 2. Detection of VEGF-RI and -RII by indirect immunoﬂuo- rescence. Slides (longitudinal sections of knee joints) were incubated with rat anti-mouse VEGF-RI and -RII mAbs (dilution 1/50) or IgG1 isotypic controls and revealed with an FITC-conjugated goat anti-rat Ab as de- scribed in Materials and Methods. a and b, Slides were treated with anti- VEGF-RI (a) and anti-VEGF-RII (b), respectively. VEGF-RI and -RII are indicated by the bright green spots in synovium and bone marrow. c and d, Slides were treated with isotypic controls for VEGF-RI (c) and VEGF-RII (d), respectively.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

doi: 10.4049/jimmunol.171.9.4853

Figure Lengend Snippet: FIGURE 2. Detection of VEGF-RI and -RII by indirect immunoﬂuo- rescence. Slides (longitudinal sections of knee joints) were incubated with rat anti-mouse VEGF-RI and -RII mAbs (dilution 1/50) or IgG1 isotypic controls and revealed with an FITC-conjugated goat anti-rat Ab as de- scribed in Materials and Methods. a and b, Slides were treated with anti- VEGF-RI (a) and anti-VEGF-RII (b), respectively. VEGF-RI and -RII are indicated by the bright green spots in synovium and bone marrow. c and d, Slides were treated with isotypic controls for VEGF-RI (c) and VEGF-RII (d), respectively.

Article Snippet: Anti-mouse VEGF and VEGF-R Abs The neutralizing polyclonal goat anti-mouse-VEGF Ab was obtained from R&D Systems Europe (Abingdon, U.K.).

Techniques: Incubation

FIGURE 6. Effects of anti-VEGF-RI and anti-VEGF-RII Abs and the tyrosine kinase inhibitor SU 11657 on the clinical course of arthritis in K/BxN transgenic mice. a and b, K/BxN transgenic mice were treated with anti-mouse VEGF-RI and -RII Abs or with an isotypic control as described in Materials and Methods. a, Anti-VEGF-RI-treated mice (; n 12) and isotypic control-treated mice (; n 11). , p 0.05. b, Anti-mouse VEGF-RII-treated mice (; n 11) and isotypic control-treated mice (; n 12). , p 0.05. c, K/BxN transgenic mice received oral SU11657 (; n 14) or placebo (; n 10) as described in Materials and Meth- ods. , p 0.05. The incidence and severity of arthritis were assessed daily. Arthritis was quantiﬁed by measuring the thickness of each paw with an electronic caliper square. The sum of the measures of the four paws (in millimeters) was used as the AI. Results are expressed as the mean SD AI.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

doi: 10.4049/jimmunol.171.9.4853

Figure Lengend Snippet: FIGURE 6. Effects of anti-VEGF-RI and anti-VEGF-RII Abs and the tyrosine kinase inhibitor SU 11657 on the clinical course of arthritis in K/BxN transgenic mice. a and b, K/BxN transgenic mice were treated with anti-mouse VEGF-RI and -RII Abs or with an isotypic control as described in Materials and Methods. a, Anti-VEGF-RI-treated mice (; n 12) and isotypic control-treated mice (; n 11). , p 0.05. b, Anti-mouse VEGF-RII-treated mice (; n 11) and isotypic control-treated mice (; n 12). , p 0.05. c, K/BxN transgenic mice received oral SU11657 (; n 14) or placebo (; n 10) as described in Materials and Meth- ods. , p 0.05. The incidence and severity of arthritis were assessed daily. Arthritis was quantiﬁed by measuring the thickness of each paw with an electronic caliper square. The sum of the measures of the four paws (in millimeters) was used as the AI. Results are expressed as the mean SD AI.

Article Snippet: Anti-mouse VEGF and VEGF-R Abs The neutralizing polyclonal goat anti-mouse-VEGF Ab was obtained from R&D Systems Europe (Abingdon, U.K.).

Techniques: Transgenic Assay, Control

FIGURE 7. Histological examination of joints from K/BxN mice was performed. Qualitative analysis of hematoxylin-phloxin-saffron-stained sections was conducted. Magniﬁcation, 25. Mice were killed on day 35. Typical aspects from two different mice in each group are presented. a and b, Joints from two placebo-treated (control) mice. a, Tarsal joint; b, knee. Mice have erosive acute arthritis, articular spaces are ﬁlled with inﬂam- matory material, synovial membranes are invaded by inﬂammatory cells, and a rheumatoid-like pannus is present. c and d, Joints from two anti- VEGF-RI-treated mice. c and d, Knee joints. Mice exhibit milder arthritis than in a and b, with no erosion and no cartilage lesions. Articular spaces are ﬁlled with edematous ﬂuid devoid of inﬂammatory cells and altered neutrophils. When present (d), the pannus is not hypertrophic or aggres- sive. e and f, Joints from two anti-VEGF-RII-treated mice. e, Right knee; f, left knee. Anti-VEGF-RII has no protective effect. Joints were similar to those observed in placebo-treated mice (a and b). Mice have erosive and destructive acute arthritis, articular spaces are ﬁlled with inﬂammatory ma- terial, synovial membranes are invaded by inﬂammatory cells, a large ne- crotic rheumatoid-like pannus is present. g and h, Joints from two mice treated with SU11657. g, Tarsal joint; h, knee joint. Mice treated with SU11657 have very few histological manifestations of arthritis, apart from a thin pannus with a ﬁbrous aspect. No bone or cartilage destruction is observed in these mice.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.

doi: 10.4049/jimmunol.171.9.4853

Figure Lengend Snippet: FIGURE 7. Histological examination of joints from K/BxN mice was performed. Qualitative analysis of hematoxylin-phloxin-saffron-stained sections was conducted. Magniﬁcation, 25. Mice were killed on day 35. Typical aspects from two different mice in each group are presented. a and b, Joints from two placebo-treated (control) mice. a, Tarsal joint; b, knee. Mice have erosive acute arthritis, articular spaces are ﬁlled with inﬂam- matory material, synovial membranes are invaded by inﬂammatory cells, and a rheumatoid-like pannus is present. c and d, Joints from two anti- VEGF-RI-treated mice. c and d, Knee joints. Mice exhibit milder arthritis than in a and b, with no erosion and no cartilage lesions. Articular spaces are ﬁlled with edematous ﬂuid devoid of inﬂammatory cells and altered neutrophils. When present (d), the pannus is not hypertrophic or aggres- sive. e and f, Joints from two anti-VEGF-RII-treated mice. e, Right knee; f, left knee. Anti-VEGF-RII has no protective effect. Joints were similar to those observed in placebo-treated mice (a and b). Mice have erosive and destructive acute arthritis, articular spaces are ﬁlled with inﬂammatory ma- terial, synovial membranes are invaded by inﬂammatory cells, a large ne- crotic rheumatoid-like pannus is present. g and h, Joints from two mice treated with SU11657. g, Tarsal joint; h, knee joint. Mice treated with SU11657 have very few histological manifestations of arthritis, apart from a thin pannus with a ﬁbrous aspect. No bone or cartilage destruction is observed in these mice.

Article Snippet: Anti-mouse VEGF and VEGF-R Abs The neutralizing polyclonal goat anti-mouse-VEGF Ab was obtained from R&D Systems Europe (Abingdon, U.K.).

Techniques: Staining, Control

Review

Structured Review

Images

Similar Products

Image Search Results